Health
DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj)-based regimens demonstrate improved rates of minimal residual disease (MRD) negativity and progression-free survival in patients with newly diagn
By: investing_za
- Dec 09 2024
- 0
- 0 Views
Share this page
Guest Posts by Easy Branches-based regimens demonstrate improved rates of minimal residual disease (MRD) negativity and progression-free survival in patients with newly diagn&url=https://easybranches.com/feed/za/health/10663223&media=https://easybranches.com/feed/uploads/2024/12/9a30bf4ac59ed5814a83bb63803f69be.jpg){kind=link}
